OracleBio selected as a CRO to join the Medicines Discovery Catapult Virtual R&D Discovery Services Platform

OracleBio Limited has formed a strategic partnership with the Medicines Discovery Catapult (MDC) by joining its Virtual R&D Discovery Services Platform. As one of the twenty-two Contract Research Organisation (CRO) partners, OracleBio will offer its digital pathology capabilities and expertise to support the needs of UK drug discovery SME’s.

The MDC’s Virtual R&D Discovery Services platform taps into the UK’s renowned contract research sector and gives drug discovery SMEs access to an unparalleled network of world-class CROs. OracleBio offers a comprehensive range of services in digital pathology that support and add value to pre-clinical and clinical R&D across numerous therapeutic areas. In particular, OracleBio’s fibrosis capabilities align with one of the key strategic areas of research of the MDC, which is fibrotic diseases.

John Waller, OracleBio’s Chief Operations Officer, commented:

“We are thrilled to become part of the CRO network in the Virtual R&D Discovery services platform. By providing tailored solutions in digital pathology, OracleBio can deliver true value to drug discovery SME’s participating in the platform.”

“There is a growing need in Pharma and Biotech to improve R&D decision making by augmenting their pipelines with quantitative insight. OracleBio has a strong footprint in digital pathology and is established as one of the leading providers of tissue-based image analysis solutions. By utilising best-in-class software to carry out tissue-based image analysis, OracleBio can generate meaningful and reproducible quantitative outputs that offer biological insight and inform data-driven decision making in R&D.”


To keep up to date with all OracleBio news and blogs, please follow us on LinkedIn and Twitter:

Find us on